We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Triple Drug Cocktail Antiviral Therapy Alleviates COVID-19 Symptoms and Shortens Hospital Stay, Finds New Study

By HospiMedica International staff writers
Posted on 12 May 2020
A new study has found that patients with mild to moderate COVID-19 who received a triple-drug treatment improved more quickly than those who received a two-drug combination.

The cocktail included three antiviral drugs: lopinavir-ritonavir (sold under the brand name Kaletra), taken orally; ribavirin, an antiviral drug for the treatment of hepatitis C, taken orally; and interferon beta-1b, an injectable drug that is used to treat multiple sclerosis and regulates inflammation and suppresses viral growth. More...
The participants in the comparison group who were treated with a two-drug combination received only lopinavir and ritonavir.

According to the new study published in The Lancet, researchers in Hong Kong followed 127 adults with COVID-19, including 86 patients who received the three-drug cocktail and 41 in the comparison group. The researchers found that patients who were given the cocktail of three antiviral drugs tested negative for the coronavirus within an average of seven days, as compared to an average of 12 days for those treated with the two-drug combination of lopinavir and ritonavir. The study also found that the triple-drug combination appeared to make the patients recover faster and cut the duration of their COVID-19 symptoms from eight days to four days.

Additionally, the triple-drug treatment appeared to be safe and both the groups experienced similar side effects, such as fever, nausea and diarrhea. The researchers now plan to conduct a larger trial to examine the effectiveness of the triple-drug treatment in critically ill COVID-19 patients.



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
New
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.